Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 9:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,465 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Healthy Humans Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)

NCT04008004
View directory record Official record
Conditions
Chronic HBV Infection
Interventions
EDP-514, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
11
States / cities
Coronado, California • Los Angeles, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Anti-Hemagglutinin (Anti-HA) Antibodies as Protection From the Flu in Healthy People

NCT01971255
View directory record Official record
Conditions
Influenza
Interventions
Ca/04/2009/H1N1r Challenge Virus
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of SYNB1020-CP-001

NCT03179878
View directory record Official record
Conditions
Healthy Volunteer, Urea Cycle Disorder
Interventions
Placebo, SYNB1020
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 64 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry

NCT04822363
View directory record Official record
Conditions
Platelet Activation Testing Before/After Anti-platelet Therapy, Healthy
Interventions
Aspirin, Clopidogrel
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 20, 2026, 9:23 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults

NCT07249463
View directory record Official record
Conditions
Cryptosporidiosis
Interventions
Cryptosporidium parvum oocysts (ABO809), EDI048, Placebo
Biological · Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy Adults

NCT00754455
View directory record Official record
Conditions
Influenza
Interventions
Influenza VLP Vaccine (recombinant), Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 49 Years
Enrollment
317 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Pembroke Pines, Florida • Kansas City, Missouri • Warwick, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 20, 2026, 9:23 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants

NCT07525544
View directory record Official record
Conditions
HIV Infections
Interventions
VH4770359, Placebo, Midazolam
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 20, 2026, 9:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)

NCT01732848
View directory record Official record
Conditions
Healthy, Hepatitis C
Interventions
BMS-986094/INX-08189, Placebo matching BMS-986094/INX-08189
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
4
States / cities
Los Angeles, California • Saint Paul, Minnesota • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2014 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children

NCT01021397
View directory record Official record
Conditions
Paramyxoviridae Infections, Virus Diseases
Interventions
rHPIV3cp45, rHPIV3cp45 placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 36 Months
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season

NCT03158038
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Monovalent Influenza Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 20, 2026, 9:23 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge

NCT02639299
View directory record Official record
Conditions
Malaria
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Novel 13C Carotenoids for Absorption and Metabolism Studies in Humans

NCT01692340
View directory record Official record
Conditions
Healthy
Interventions
Isotopically labeled lycopene, phytoene or phytofluene
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
21 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fish Oil vs. Placebo on Subjective Effects of Alcohol

NCT03010917
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Fish Oil with ethanol and placebo ethanol infusions, Placebo with ethanol and placebo ethanol infusions
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805

NCT01424540
View directory record Official record
Conditions
Hepatitis C
Interventions
GSK2336805 150mg, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Probiotics (L. Helveticus, B. Longum, and B. Bifidum) on Immune Function and Digestive Health

NCT01709825
View directory record Official record
Conditions
Healthy
Interventions
Probiotic- Bifidobacterium Bifidum, Sugar Pill, Probiotic- Lactobacillus helveticus, Probiotic- Bifidobacterium longum ss. Infantis R0033
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
583 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 29, 2015 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First-in-Human Study of SBP-9330 in Healthy Subjects

NCT04948827
View directory record Official record
Conditions
Smoking Cessation
Interventions
SBP-9330, Placebo
Drug
Lead sponsor
Camino Pharma, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

NCT02748694
View directory record Official record
Conditions
Healthy Volunteers, Schizophrenia
Interventions
TAK-041, TAK-041 Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older

NCT06744205
View directory record Official record
Conditions
Influenza, Healthy Volunteers
Interventions
Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1, TIV mRNA-neuraminidase (NA), TIV mRNA-HA Vaccine 2, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza Vaccine High Dose
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
50 Years and older
Enrollment
1,162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
21
States / cities
Birmingham, Alabama • Mobile, Alabama • Tempe, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP-938 in Healthy Subjects

NCT03384823
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-938, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immune Response Following Seasonal Influenza Vaccination

NCT03163342
View directory record Official record
Conditions
Influenza
Interventions
Licensed seasonal influenza vaccine
Biological
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects

NCT00845429
View directory record Official record
Conditions
Influenza, Orthomyxoviruses, Myxovirus Infection
Interventions
Influenza virus vaccine - cell-based (2007-2008 Formulation), Influenza virus vaccine (2007-2008 Formulation)
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 49 Years
Enrollment
729 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
15
States / cities
Hoover, Alabama • Mobile, Alabama • Tucson, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects

NCT01610388
View directory record Official record
Conditions
Infections, Bacterial
Interventions
500mg IV GSK1322322/placebo, 1000mg oral GSK1322322/placebo, 1000mg IV GSK1322322/placebo, 1500mg oral GSK1322322/placebo dose, 1500mg IV GSK1322322/placebo, 2000mg IV GSK1322322J/placebo, 3000mg IV GSK1322322J/placebo, 1000mg IV GSK1322322J/placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101

NCT04111666
View directory record Official record
Conditions
Healthy
Interventions
AL101, Placebo
Biological · Other
Lead sponsor
Alector Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 20, 2026, 9:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD

NCT02918929
View directory record Official record
Conditions
Presumptive NAFLD
Interventions
EDP 305, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 20, 2026, 9:23 AM EDT